Active substance abemaciclib
Holder S.A. Eli Lilly N.V.
Status Running
Indication in combination with Endocrine Therapy as the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, nodepositive early breast cancer at high risk of recurrence
Public documents Approbation
  Information for  the patient
  Informed consent
Last update 28/07/2022


Last updated on 05/08/2022